Korean Market
EXCH
GemVax & KAEL
★★★

Largest Shareholder Gem & Company Expands Pledged Shares to 5.23 Million; Stake Could Plummet to 0.51% If All Executed, Risking Loss of Control

 
EXCH
GemVax & KAEL
★★★★

Major Shareholder's Pledge Expansion Intensifies Dilution and Control Change Risk

 
EXCH
GemVax & KAEL
★★★★

Largest Shareholder Gem&Company Increases Pledged Shares to 5.16M; Risk of Stake Collapse to 0.66% upon Enforcement

 
EXCH
GemVax & KAEL
★

GemVax Completes 7 Billion Won Premium Convertible Bond Issuance: Secures R&D Funding While Dilution Risk Persists

 
MATR
GemVax & KAEL
★

Decision to issue KRW 7 billion premium convertible bonds (conversion price KRW 18,659, +12% vs market)

 
MATR
GemVax & KAEL
★

17 billion won 3rd-party allotment, offering price 26,470 won (premium over current price)

 
EXCH
GemVax & KAEL
★★★

Additional Pledge by Largest Shareholder Risks Stake Drop to 0.87% if All Pledges Executed

 
OWNR
GemVax & KAEL
★

No change in stake at 25.90%, but pledged shares increase to 4,699,674 (10.62%)

 
EXCH
GemVax & KAEL
★★

Major shareholder Gem & Company pledges 84.7% of holdings; stake could drop to 1.88% if executed

 
MATR
GemVax & KAEL
★

Decision to Issue Convertible Bonds - Put Option Available After 1 Year, Transfer Restricted for 1 Year

 
EXCH
GemVax & KAEL
★★

Supreme Court Damage Lawsuit Withdrawn via Settlement - 17.8 Billion Won Settlement and Convertible Bond Issuance

 
EXCH
GemVax & KAEL
★★

Acquisition of 35.85% Stake in BioVille for 12.4 Billion Won via Litigation Settlement

 
MATR
GemVax & KAEL
★★

Decision to Issue Convertible Bonds for Supreme Court Lawsuit Settlement

 
EXCH
GemVax & KAEL
★★★

Major Shareholder Additional Pledge and Financial Risk Intensification

 
PERI
GemVax & KAEL
★

GemVax&KAEL: 1Q26 Consolidated Operating Loss of 7.6B KRW, Net Loss of 14.9B KRW; Debt Ratio Improves to 88.6%; GV1001 PSP Conditional Approval Filed